To monitor the aberrant AKT activity in this setting, Akt-FRET biosensor mice were crossed with the Pten−/+ or mutant PtenG129E/+ models, which further developed mammary tumors by 377 ± 137 days. This evidence concerns the gene AKT1 and breast cancer.